Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30


NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.

Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T, Schäfer C, Stintzing S, Giessen C, Modest DP, Ridwelski K, Heinemann V.

Int J Cancer. 2015 Aug 1;137(3):678-85. doi: 10.1002/ijc.29403. Epub 2015 Feb 25.


Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.

Gamba S, Camaj P, Heinemann V, Laubender RP, Wang Y, Zhao Y, Stintzing S, Giessen C, Boeck S, Haertl C, Bruns CJ, Modest DP.

Anticancer Drugs. 2015 Apr;26(4):371-8. doi: 10.1097/CAD.0000000000000196.


Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3.

Haas M, Kern C, Kruger S, Michl M, Modest DP, Giessen C, Schulz C, von Einem JC, Ormanns S, Laubender RP, Holdenrieder S, Heinemann V, Boeck S.

Tumour Biol. 2015 Apr;36(4):2631-40. doi: 10.1007/s13277-014-2885-x. Epub 2014 Dec 4.


Cost-Effectiveness Analysis of Ugt1a1 Genotyping Before Colorectal Cancer Treatment with Irinotecan.

Butzke B, Oduncu F, Heinemann V, Pfeufer A, Giessen C, Stollenwerk B, Rogowski W.

Value Health. 2014 Nov;17(7):A643. doi: 10.1016/j.jval.2014.08.2326. Epub 2014 Oct 26. No abstract available.


Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient.

Kneidinger N, Giessen C, von Wulffen W, Milger K, Schramm R, Jäger G, Nitschko H, Striebinger H, Behr J, Neurohr C.

Int J Infect Dis. 2014 Nov;28:140-2. doi: 10.1016/j.ijid.2014.06.009. Epub 2014 Sep 26.


Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer.

Giessen C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, Michl M, Heinemann V, Stieber P, Schulz C.

Tumour Biol. 2014 Oct;35(10):10237-48. doi: 10.1007/s13277-014-2338-6. Epub 2014 Jul 17.


Tumor markers CEA and CA 19-9 correlate with radiological imaging in metastatic colorectal cancer patients receiving first-line chemotherapy.

Michl M, Koch J, Laubender RP, Modest DP, Giessen C, Schulz Ch, Heinemann V.

Tumour Biol. 2014 Oct;35(10):10121-7. doi: 10.1007/s13277-014-2280-7. Epub 2014 Jul 15.


Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials.

Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Schulz C, Mansmann U, Heinemann V.

Acta Oncol. 2015 Feb;54(2):187-93. doi: 10.3109/0284186X.2014.938830. Epub 2014 Jul 14. Review.


Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial.

von Einem JC, Heinemann V, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Decker T, Klein S, Held S, Jung A, Kirchner T, Haas M, Holch J, Michl M, Aubele P, Boeck S, Schulz C, Giessen C, Stintzing S, Modest DP.

J Cancer Res Clin Oncol. 2014 Sep;140(9):1607-14. doi: 10.1007/s00432-014-1678-3. Epub 2014 May 10.


Resection of pulmonary metastases from colon and rectal cancer: factors to predict survival differ regarding to the origin of the primary tumor.

Meimarakis G, Spelsberg F, Angele M, Preissler G, Fertmann J, Crispin A, Reu S, Kalaitzis N, Stemmler M, Giessen C, Heinemann V, Stintzing S, Hatz R, Winter H.

Ann Surg Oncol. 2014 Aug;21(8):2563-72. doi: 10.1245/s10434-014-3646-1. Epub 2014 Mar 26.


Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment).

Modest DP, Schulz C, von Weikersthal LF, Quietzsch D, von Einem JC, Schalhorn A, Vehling-Kaiser U, Laubender RP, Giessen C, Stintzing S, Heinemann V.

Anticancer Drugs. 2014 Feb;25(2):212-8. doi: 10.1097/CAD.0000000000000041.


Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group.

Giessen C, Graeven U, Laubender RP, Modest DP, Schulz C, Porschen R, Schmiegel W, Reinacher-Schick A, Hegewisch-Becker S, Stintzing S, Heinemann V.

Ann Oncol. 2013 Dec;24(12):3051-5. doi: 10.1093/annonc/mdt402. Epub 2013 Oct 14.


Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial.

Giessen C, Fischer von Weikersthal L, Laubender RP, Stintzing S, Modest DP, Schalhorn A, Schulz C, Heinemann V.

Br J Cancer. 2013 Sep 17;109(6):1428-36. doi: 10.1038/bjc.2013.475. Epub 2013 Aug 20.


Clinical relevance and utility of cetuximab-related changes in magnesium and calcium serum levels.

Stintzing S, Fischhaber D, Mook C, Modest DP, Giessen C, Schulz C, Haas M, Boeck S, Michl M, Stemmler J, Laubender RP, Heinemann V.

Anticancer Drugs. 2013 Oct;24(9):969-74. doi: 10.1097/CAD.0b013e32836411bc.


Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial.

Giessen C, Laubender RP, Fischer von Weikersthal L, Schalhorn A, Modest DP, Stintzing S, Haas M, Mansmann UR, Heinemann V.

Cancer Sci. 2013 Jun;104(6):718-24. doi: 10.1111/cas.12148. Epub 2013 Apr 15.


Combined resection of colorectal hepatic-pulmonary metastases shows improved outcome over chemotherapy alone.

Meimarakis G, Angele M, Conrad C, Schauer R, Weidenhagen R, Crispin A, Giessen C, Preissler G, Wiedemann M, Jauch KW, Heinemann V, Stintzing S, Hatz RA, Winter H.

Langenbecks Arch Surg. 2013 Feb;398(2):265-76. doi: 10.1007/s00423-012-1046-1. Epub 2013 Jan 13.


Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial.

Modest DP, Laubender RP, Stintzing S, Giessen C, Schulz C, Haas M, Mansmann U, Heinemann V.

Acta Oncol. 2013 Jun;52(5):956-62. doi: 10.3109/0284186X.2012.752580. Epub 2012 Dec 18.


Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.

Giessen C, Laubender RP, Ankerst DP, Stintzing S, Modest DP, Mansmann U, Heinemann V.

Clin Cancer Res. 2013 Jan 1;19(1):225-35. doi: 10.1158/1078-0432.CCR-12-1515. Epub 2012 Nov 13.


Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.

Stintzing S, Kapaun C, Laubender RP, Jung A, Neumann J, Modest DP, Giessen C, Moosmann N, Wollenberg A, Kirchner T, Heinemann V.

Int J Cancer. 2013 Jan 1;132(1):236-45. doi: 10.1002/ijc.27654. Epub 2012 Jun 26.


Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis.

Modest DP, Reinacher-Schick A, Stintzing S, Giessen C, Tannapfel A, Laubender RP, Brodowicz T, Knittelfelder R, Vrbanec D, Schmiegel W, Heinemann V, Zielinski CC.

Anticancer Drugs. 2012 Jul;23(6):666-73. doi: 10.1097/CAD.0b013e328352ff1d.


FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.

Stintzing S, Fischer von Weikersthal L, Decker T, Vehling-Kaiser U, Jäger E, Heintges T, Stoll C, Giessen C, Modest DP, Neumann J, Jung A, Kirchner T, Scheithauer W, Heinemann V.

Ann Oncol. 2012 Jul;23(7):1693-9. doi: 10.1093/annonc/mdr571. Epub 2012 Jan 4.


Primary effusion lymphoma (PEL) without effusion: a patient case report of a PEL solid variant.

Giessen C, Di Gioia D, Huber B, Seppi B, Graser A, Duerr HR, Mayr D, Kirchner T, Rosenwald A, Forstpointner R, Heinemann V, Bogner JR, Ostermann H.

J Clin Pathol. 2012 Feb;65(2):189-90. doi: 10.1136/jclinpath-2011-200279. Epub 2011 Oct 19. No abstract available.


The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: an analysis of the AIO KRK-0104-trial.

Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, Haas M, Neumann J, Boeck S, Kirchner T, Heinemann V, Stintzing S.

Int J Cancer. 2012 Aug 15;131(4):980-6. doi: 10.1002/ijc.26467. Epub 2011 Nov 17.


[Colon cancer: adjuvant chemotherapy and aftercare].

Heinemann V, Giessen C, Modest D, Moosmann N, Stintzing S.

MMW Fortschr Med. 2011 Sep 1;153(35):34-6. German. No abstract available.


A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial.

Giessen C, von Weikersthal LF, Hinke A, Stintzing S, Kullmann F, Vehling-Kaiser U, Mayerle J, Bangerter M, Denzlinger C, Sieber M, Teschendorf C, Freiberg-Richter J, Schulz C, Modest DP, Moosmann N, Aubele P, Heinemann V.

BMC Cancer. 2011 Aug 23;11:367. doi: 10.1186/1471-2407-11-367.


Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status.

Modest DP, Stintzing S, Laubender RP, Neumann J, Jung A, Giessen C, Haas M, Aubele P, Schulz C, Boeck S, Stemmler HJ, Kirchner T, Heinemann V.

Anticancer Drugs. 2011 Oct;22(9):913-8. doi: 10.1097/CAD.0b013e3283493160.


Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial.

Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Giessen C, Moosmann N, Heinemann V.

Br J Cancer. 2011 Jul 12;105(2):206-11. doi: 10.1038/bjc.2011.227.


Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer.

Giessen C, Stintzing S, Laubender RP, Ankerst DP, Schulz C, Moosmann N, Modest DP, Schalhorn A, von Weikersthal LF, Heinemann V.

Clin Colorectal Cancer. 2011 Dec;10(4):317-24. doi: 10.1016/j.clcc.2011.03.027. Epub 2011 May 12.


Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.

Fischer von Weikersthal L, Schalhorn A, Stauch M, Quietzsch D, Maubach PA, Lambertz H, Oruzio D, Schlag R, Weigang-Köhler K, Vehling-Kaiser U, Schulze M, Truckenbrodt J, Goebeler M, Mittermüller J, Bosse D, Szukics B, Grundeis M, Zwingers T, Giessen C, Heinemann V.

Eur J Cancer. 2011 Jan;47(2):206-14. doi: 10.1016/j.ejca.2010.09.022.


UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer.

Schulz C, Heinemann V, Schalhorn A, Moosmann N, Zwingers T, Boeck S, Giessen C, Stemmler HJ.

World J Gastroenterol. 2009 Oct 28;15(40):5058-66.

Supplemental Content

Loading ...
Support Center